AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$AORT

Mackin James P sold $2.0M of AORT

Mackin James P (President & CEO) sold 70,000 shares of ARTIVION, INC. (AORT) at $28.96 ($2.03M total) on 2026-08-19.

Original reporting
SEC EDGAR · Mackin James P
Published Aug 20, 2026, 6:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AORT
Bearish
medium confidence
Mentioned
$AORT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTBearishLow
01

Why it matters

The disclosed sale represents a fresh data point for traders assessing insider sentiment and may influence short‑term price action.

02

Market read

Direct relevance to Artivion shareholders; indirect relevance to biotech sector investors monitoring insider activity.

03

What to watch

Potential tax planning or liquidity needs for the executive; no immediate change in company operations.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 filings provide the first public record of insider transactions, offering transparency into executive holdings.

Company-level read

Ticker impact

$AORTBearishMedium confidence
Context

SEC Form 4 disclosed President & CEO Mackin James P sold 70,000 shares of Artivion at $28.96 each, total $2.03M.

Expected impact

modest short‑term downside pressure

Evidence & confidence

A $2M sale by a top executive is material for a mid‑cap biotech, but the size relative to total float is limited.

Market effects

Sector

May raise concerns for biotech sector insiders and could prompt scrutiny of other executive holdings.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond Artivion shareholders.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Company
    Artivion, Inc.

    Biotech firm developing medical devices and therapies.

  • Executive
    Mackin James P

    President & CEO of Artivion.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AORT insider trading history →

Related articles

AUG 19
$AORTMed

Why Artivion (AORT) Stock Is Trading Up Today

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

financialcontent.com2 min
AUG 14
$AORTMedAI 8/10

Artivion (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

fool.com7 min
AUG 10
$AORTMed

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.

local3news.com3 min
AUG 6
$AORTHigh

ARTIVION, INC. (AORT): Results of Operations and Financial Condition

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Second Quarter 2026

SEC EDGAR 8-K7 min